Vaccine protection against simian immunodeficiency virus by recombinant strains of herpes simplex virus
Vaccine protection against simian immunodeficiency virus by recombinant strains of herpes simplex virus
复制标题
DOI：
10.1128/jvi.74.17.7745-7754.2000
复制
发表时间：
2000-09-01
影响因子：
5.4
通讯作者：
Desrosiers, RC
中科院分区：
文献类型：
--
作者：
Murphy, CG;Lucas, WT;Desrosiers, RC
有效的艾滋病疫苗可能需要开发能够引发持久免疫反应的新型载体。在这里，我们报告的开发和使用的复制能力和复制缺陷株的重组单纯疱疹病毒（HSV），表达包膜和Nef抗原的猴免疫缺陷病毒（SIV）。HSV重组体诱导的抗包膜抗体应答在最后一次给药后持续在相对稳定的水平数月。用重组HSV接种的7只恒河猴中有2只受到牢固的保护，另一只在最后一次疫苗给药后22周用致病性SIVmac239直肠攻击后显示病毒载量持续降低。因此，HSV载体显示出很大的希望，能够引起持久的免疫应答，并提供持久的保护，以防止艾滋病。
An effective vaccine for AIDS may require development of novel vectors capable of eliciting long-lasting immune responses. Here we report the development and use of replication-competent and replication-defective strains of recombinant herpes simplex virus (HSV) that express envelope and Nef antigens of simian immunodeficiency virus (SIV). The HSV recombinants induced antienvelope antibody responses that persisted at relatively stable levels for months after the last administration, Two of seven rhesus monkeys vaccinated with recombinant HSV were solidly protected, and another showed a sustained reduction in viral load following rectal challenge with pathogenic SIVmac239 at 22 weeks following the last vaccine administration. HSV vectors thus show great promise for being able to elicit persistent immune responses and to provide durable protection against AIDS.